Biomedical Resource Core

摘要-生物医学资源核心 肾脏研究中一个尚未解决的主要挑战是，大多数传统的途径和方法无法 利用组织功能、结构和细胞表型的复杂性。纳米技术的创新 提供强大的工具、试剂和平台，在以下几个领域超越传统方法 医学，如令人震惊的成功，包括信使核糖核酸疫苗开发和肿瘤学。 然而，这些资源在很大程度上没有被肾脏团体利用，也不能单独使用。 实验室或机构。西北大学(NU)是纳米技术的全球领导者和先驱之家 设在国际纳米医学研究所(IIN)。在西北奥布莱恩·肯尼的任期内 中心(NU-GoKIDNEY)，我们利用NU的这一独特的科学专业知识来建立和优化服务 利用纳米技术的力量为肾脏研究人员服务，努力开发出更多 肾脏疾病的有效治疗。拟议的核心建立在通过 Nu-GoKIDNEY提供的核心B纳米治疗服务，其中包括1)长期致力于 南大纳米医学带头人作为核心领导和执行成员的肾脏研究 委员会，2)肾脏研究人员对纳米技术服务表现出兴趣，他们要求 纳米技术服务和提交的P&F提案侧重于纳米医学解决方案。这些都建立了 服务现在构成了以下具体目标的基础：目标1将建立一个生物医学资源核心 要实施服务设计，以便将所需的有效负载精确定位到 肾脏；目标2将制定标准操作规程，并对所提供的所有服务执行内部质量保证/质量控制和标准操作规程； 目标3将确保国家通过多个机制获得资源，这些机制与 财团。总之，NU-Biomedical资源核心将利用纳米技术的力量来 促进肾脏健康，并为整个调查人员提供易于访问的核心服务门户 我们。

SUMMARY-BIOMEDICAL RESOURCE CORE A major unmet challenge in kidney research is the inability of most traditional approaches and methods to harness the complexity of tissue function, structure, and cellular phenotypes. Innovations in nanotechnology provide powerful tools, reagents, and platforms that outperform traditional approaches in several areas of medicine, as clearly shown by stunning successes including mRNA vaccine development and oncology. Nevertheless, these resources are largely untapped by the kidney community and are unavailable in individual labs or institutions. Northwestern University (NU) is home to global leaders and pioneers in nanotechnology housed in the International Institute of Nanomedicine (IIN). During the tenure of the Northwestern O'Brien Kidney Center (NU-GoKIDNEY), we leveraged this unique scientific expertise at NU to establish and optimize services that deploy the power of nanotechnology in the service of kidney researchers in their efforts to develop more effective treatments for kidney diseases. The proposed Core builds on the momentum established through the Core B nanotherapeutic services offered by NU-GoKIDNEY, which includes 1) longstanding commitment to kidney research of nanomedicine leaders at NU who served as Core leaders and members of our Executive committee, 2) demonstrated interest in nanotechnology services by kidney investigators who requested nanotechnology services and submitted P&F proposals focused on nanomedicine solutions. These established services now form the basis of the following Specific Aims: Aim 1 will establish a Biomedical Resource Core to implement a service design for precision targeting of desired payloads to specific cells and sub-regions within the kidney; Aim 2 will establish SOPs and implement internal QA/QC and SOP protocols for all services offered; Aim 3 will ensure national access to resources by multiple mechanisms, that operate in collaboration with the consortium. In summary, the NU- Biomedical Resource Core will harness the power of nanotechnology to advance kidney health and provide an easily accessed portal to Core services for investigators throughout the US.